CGEM Surges 36.54% on Analyst Upgrades, Strategic Oncology Focus

The share price rose to its highest level so far this month, with an intraday gain of 40.76%.

Cullinan Therapeutics (CGEM) surged 36.54% on November 25, extending its three-day rally to 53.02%. The rally follows a series of analyst upgrades and a strategic focus on oncology and autoimmune disease therapies. BTIG analyst Julian Harrison raised the price target to $38 from $32, while HC Wainwright & Co. increased its target to $26. Analysts highlight CGEM’s diversified pipeline, which includes clinical-stage assets targeting cancer and immune-driven conditions, as a key differentiator in a sector favoring personalized therapies.

Wall Street’s consensus reflects strong confidence, with nine analysts averaging a $26 price target—implying a 118.4% upside from the current price. While Morgan Stanley’s recent 20% reduction in its target to $28 introduced caution, the broader “Buy” rating trend across 11 firms underscores sustained optimism. CGEM’s alignment with high-demand therapeutic areas and its ability to translate scientific insights into drug candidates further reinforce its growth potential. The biopharma sector’s focus on immunotherapy and precision medicine has amplified interest in companies like CGEM, positioning it to benefit from ongoing industry momentum.